BIOMARIN PHARMACEUTICAL INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $101.60 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $101.60, a 18.13% increase from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $86.01, a 4.01% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $82.69, a 4.41% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $79.20, a 3.72% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $101.60 10-K · filed 2026-02-26 |
| 2024-12-31 | $86.01 10-K · filed 2025-02-24 |
| 2023-12-31 | $82.69 10-K · filed 2024-02-26 |
| 2022-12-31 | $79.20 10-K · filed 2023-02-27 |
| 2021-12-31 | $82.26 10-K · filed 2022-02-25 |
| 2020-12-31 | $86.07 10-K · filed 2021-02-26 |
| 2019-12-31 | $82.24 10-K · filed 2020-02-27 |
| 2018-12-31 | $86.46 10-K · filed 2019-02-28 |
| 2017-12-31 | $92.98 10-K · filed 2018-02-26 |
| 2016-12-31 | $84.78 10-K · filed 2017-02-27 |
| 2015-12-31 | $63.79 10-K · filed 2016-02-29 |
| 2014-12-31 | $49.88 10-K · filed 2015-03-02 |
| 2013-12-31 | $34.43 10-K · filed 2014-02-26 |
| 2012-12-31 | $26.14 10-K · filed 2013-02-26 |
| 2011-12-31 | $24.70 10-K · filed 2013-02-26 |
| 2010-12-31 | $23.80 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |